Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 09, 2026 10:30 ET | Source: Novartis Pharma AG

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern USPurpose-built facility will strengthen Novartis RLT...
January 09, 2026 10:30 ET | Source: Novartis Pharma AG

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern USPurpose-built facility will strengthen Novartis RLT...
January 09, 2026 07:00 ET | Source: Avance Clinical

Avance Clinical to Showcase New Early Phase Center of Excellence at Biotech Showcase 2026

Avance Clinical will meet biotech sponsors at Biotech Showcase 2026 in San Francisco, highlighting the launch of the new Early Phase Center of Excellence.
January 08, 2026 08:00 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib

Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been...
January 08, 2026 07:00 ET | Source: Enara bio

Enara Bio Enters 2026 with Dark Antigen Licensing to Boehringer Ingelheim, Appointment of Chief Medical Officer and Plans to Advance DARKFOX T-cell Engager into First-in-Human Studies

Boehringer Ingelheim exercises option to license additional Dark Antigens from a wider array of tumor types, expanding Enara’s eligibility for milestone payments under existing collaboration Scott...
January 08, 2026 04:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors

VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina”), a biopharmaceutical company advancing innovative cancer therapies...
January 07, 2026 16:00 ET | Source: Immuneering Corporation

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
January 07, 2026 13:15 ET | Source: Ottimo Pharma Limited

Ottimo Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for OTP-01, a First-in-Class, Dual-Paratopic, Single-Agent, Anti-PD-1/VEGFR2 Antibody

First patient dosed and study open in leading oncology centers in US and AustraliaPhase I/IIA adaptive study aims to assess and optimize the dose of OTP-01 and provide safety, tolerability, and early...
January 07, 2026 12:03 ET | Source: AB Science

AB Science annonce un quatrième cas consécutif de réponse avec la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute, sur la base des données de phase 1

COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE UN QUATRIÈME CAS CONSÉCUTIF DE RÉPONSE AVEC LA COMBINAISON D’AB8939 ET DU VENETOCLAX DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË RÉFRACTAIRE OU EN...
January 07, 2026 12:03 ET | Source: AB Science

AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia

PRESS RELEASE AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA...